Verona Pharma PLC
NASDAQ:VRNA
Verona Pharma PLC
NASDAQ:VRNA
Price:
14.8 USD
-0.54%
Market Closed
Updated:
May 9, 2024
Verona Pharma PLC
Cash from Operating Activities
|
Verona Pharma PLC
Cash from Operating Activities Peer Comparison
Comparables:
GSK
AZN
INDV
HIK
DPH
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Cash from Operating Activities
-$50.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Cash from Operating Activities
£7.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
1%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Cash from Operating Activities
$9.7B
|
CAGR 3-Years
14%
|
CAGR 5-Years
33%
|
CAGR 10-Years
4%
|
|
|
Indivior PLC
LSE:INDV
|
Cash from Operating Activities
-$334m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Cash from Operating Activities
$608m
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Cash from Operating Activities
£63.6m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
0%
|
CAGR 10-Years
6%
|
See Also
What is Verona Pharma PLC's Cash from Operating Activities?
Cash from Operating Activities
-50.2m
USD
-50.2m
USD
Based on the financial report for Dec 31, 2023, Verona Pharma PLC's Cash from Operating Activities amounts to -50.2m USD.
What is Verona Pharma PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-4%
-4%
Over the last year, the Cash from Operating Activities growth was 16%. The average annual Cash from Operating Activities growth rates for Verona Pharma PLC have been -4% over the past three years .
You don't have any saved screeners yet
